Nkarta (NKTX) Upgraded to Buy: Here's What You Should Know
Nkarta (NKTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
3 Undervalued Stocks Primed for a 2X Return
For investors looking to maximize profits, marking the appropriate cheap stocks is essential. Here, the focus is on three exceptional businesses, each with solid arguments for being included in a sharp investment plan.
Nkarta: Finally An Attractive Valuation
Nkarta Inc. is using natural killer cells engineered with CARs and membrane-bound IL-15 to target autoimmune diseases and oncology. The company's off-the-shelf availability and superior safety profile make it an attractive option for patients, providers, and payers. Nkarta is targeting large markets, such as lupus nephritis and non-Hodgkin lymphoma, with the potential to produce blockbuster therapies.
